Saricilar Erin Cihat, Huang Sarah
Department of Vascular Surgery, Liverpool Hospital, Sydney, Australia.
Department of Plastic Surgery, Royal North Shore Hospital, Sydney, Australia.
Arch Plast Surg. 2021 Jul;48(4):433-439. doi: 10.5999/aps.2020.02306. Epub 2021 Jul 15.
Acellular dermal matrices (ADM) are a novel graft. The goal of this systematic review is to evaluate the evidence behind differences in human and porcine ADM, irrelevant of manufacturing method, and to determine if there is enough of an evidence base to change clinical practice. An extensive literature search was performed through MEDLINE and Embase with search terms defining a population, intervention and outcome. Title and abstract exclusion were performed with other exclusion criteria. In 191 articles were found after exclusion of duplicates, with only 29 remaining following exclusions. Ten studies were found to have level I and II evidence (I=3, II=8), of which two were histopathological, one was an animal model, one was a systematic review, and six were clinical. The remaining studies were reviewed and considered for discussion, but did not hold high enough standards for medical evidence. Strong clinical evidence already exists for the use of human ADM, but questions of access, cost, and ethics require consideration of a xenograft. Histopathologically, evidence suggests minimal long-term differences between human and porcine ADM, although there is a short acute immune response with porcine ADM. Clinically, there is limited difference in outcomes, with a small range in effect of different ADM preparations. Considering the effectiveness of ADM in wound healing, more high-level research with appropriate statistical analysis to facilitate a future meta-analysis is recommended to justify a transition from human to porcine ADM.
脱细胞真皮基质(ADM)是一种新型移植物。本系统评价的目的是评估与制造方法无关的人源和猪源ADM差异背后的证据,并确定是否有足够的证据基础来改变临床实践。通过MEDLINE和Embase进行了广泛的文献检索,检索词定义了研究人群、干预措施和结果。根据其他排除标准对标题和摘要进行了排除。排除重复文献后共找到191篇文章,经过进一步排除后仅剩下29篇。发现有10项研究具有I级和II级证据(I级=3项,II级=8项),其中两项是组织病理学研究,一项是动物模型研究,一项是系统评价,六项是临床研究。对其余研究进行了审查并考虑进行讨论,但它们不符合足够高的医学证据标准。人源ADM的使用已经有了强有力的临床证据,但获取、成本和伦理问题需要考虑异种移植物。组织病理学证据表明,人源和猪源ADM之间的长期差异极小,不过猪源ADM会引发短暂的急性免疫反应。临床上,不同ADM制剂的疗效差异有限,结果差异不大。考虑到ADM在伤口愈合中的有效性,建议开展更多采用适当统计分析的高水平研究,以便将来进行荟萃分析,从而为从人源ADM转向猪源ADM提供依据。